Publication: 3618

Publication: 3618

Prognostic value of immune gene-expression signatures (iGES) vs. tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: a combined analysis of CALGB 40601 (Alliance) and PAMELA trials.

URL

Google Scholar

Citation:: Annals of Oncology vol 32 (suppl_5) 120MO, p 409 S407-S446

Meeting Instance:: ESMO 2021
Year:: 2021
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3779 3780

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: GlaxoSmithKline
Grants:: U10CA180821, U10CA180882, U24CA196171; NCI SPORE (P50-CA58823), R01-CA229409, Instituto de Salud Carlos III - PI16/00904

Corr. Author:
Authors:: Aranzazu Fernandez-Martinez Tomás Pascual Baljit Singh Paolo Nuciforo Katherine A. Hoadley Naim U. Rashid Patricia A. Spears Ian Krop David Hillman Ann Partridge Aleix Prat Lisa Carey Charles Perou

Networks:: LAPS-CT018, LAPS-MA036, LAPS-NC007

Study: CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: